Novartis registers Phase 2 VEXAS trial for arumakimig; posts MS treatment-pattern study results
Novartis has two new registry entries this week: a Phase 2 trial testing arumakimig in VEXAS syndrome and a completed observational study on multiple sclerosis treatment switching.
Novartis filed two new clinical trial registrations this week covering an autoinflammatory disease and a real-world MS analysis.
- Novartis registered "VEX-AR," a Phase 2, randomized, double-blind, placebo-controlled 52-week study of arumakimig (MAS825) in patients with VEXAS syndrome, a study evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids, with participants randomized 1:1 to arumakimig or placebo.1 The trial is not yet recruiting, with an estimated enrollment of 120 participants1 and a primary outcome measuring participants achieving improvement of key VEXAS manifestations and oral glucocorticoid reduction at Week 52.1
- Novartis completed a retrospective observational study on multiple sclerosis treatment patterns, sponsored under study ID CBAF312AUS18, with the aim of describing real-world treatment patterns after relapsing on platform disease-modifying therapies, in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs, as well as time to switching DMTs after relapse.2 The study enrolled 753 participants2 and compared treatment failure rates in patients who escalate to high-efficacy DMTs versus those who remain on platform DMTs following initial relapse.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.